Robert W Duggan
Director at Pulse Biosciences, Inc. (PLSE); CEO at Summit Therapeutics Inc. (SMMT)
Purchase track record
Strong record. Based on 5 purchases with a full 90 days of price history.
98
Avg. 90-day return+42.0%
vs. S&P 500+38.7%
Beat the market60%
Paper profit on buys+$62.4M
Total bought / sold$77.9M / $0
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Jun 12SEC | SMMTSummit Therapeutics Inc. | Buy | 3,810,000573,883,879 held (+1%) | $13.12 | $50.0M | +34.1% |
| Jun 4SEC | SMMTSummit Therapeutics Inc. | Buy | 100,00025,824,474 held (+0%) | $14.60 | $1.5M | +20.5% |
| May 15SEC | PLSEPulse Biosciences, Inc. | Buy | 660,23348,370,047 held (+1%) | $19.69 | $13.0M | +173.3% |
| May 11SEC | PLSEPulse Biosciences, Inc. | Buy | 660,23348,211,433 held (+1%) | $19.69 | $13.0M | +173.3% |
| Oct 23SEC | SMMTSummit Therapeutics Inc. | Buy | 26,68076,680 held (+53%) | $18.74 | $500K | -6.1% |
- Buy
CEO Robert W Duggan bought $50.0M of SMMT at $13.12 — largest purchase by this insider in our records.
- Buy
CEO Robert W Duggan bought $1.5M of SMMT at $14.60 — largest purchase by this insider in our records.
- Buy
Director Robert W Duggan bought $13.0M of PLSE at $19.69 — first open-market purchase in our records.
- Buy
CEO Robert W Duggan bought $500K of SMMT at $18.74 — first open-market purchase in our records; raises the stake by 53%.